Cargando…

Antibacterial Activity of Eravacycline Against Carbapenem-Resistant Gram-Negative Isolates in China: An in vitro Study

OBJECTIVE: Eravacycline is a novel, fully synthetic fluorocycline antibiotic being developed for the treatment of serious infections, with a broad-spectrum antimicrobial activity, including against carbapenem-resistant gram-negative bacteria (CRGNB). However, the in vitro activity of eravacycline ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zou, Xuehan, Jin, Shaojun, Chen, Lingxia, Li, Jie, Zhang, Xiaofan, Zhou, Hua, Li, Xi, Huang, Haijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120866/ https://www.ncbi.nlm.nih.gov/pubmed/37090037 http://dx.doi.org/10.2147/IDR.S396910

Ejemplares similares

In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland
por: Brauncajs, Małgorzata, et al.
Publicado: (2023)

In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017
por: Morrissey, Ian, et al.
Publicado: (2020)

728. Activity of Eravacycline Against Contemporary Gram-Negative Clinical Isolates From New York City Hospitals
por: Iregui, Alejandro, et al.
Publicado: (2019)

1613. Global 2018 Surveillance of Eravacycline Against Gram-negative Pathogens, Including Multi-drug Resistant Isolates
por: Lijfrock, Virgil, et al.
Publicado: (2020)

In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017
por: Morrissey, Ian, et al.
Publicado: (2020)

Emergence of Plasmids Co-Harboring Carbapenem Resistance Genes and tmexCD2-toprJ2 in Sequence Type 11 Carbapenem Resistant Klebsiella pneumoniae Strains
por: Li, Xi, et al.
Publicado: (2022)

915. Global 2018 Surveillance of Eravacycline Against Gram-positive Pathogens, Including Resistant Isolates
por: Morgan, Steven, et al.
Publicado: (2020)

Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii
por: Alosaimy, Sara, et al.
Publicado: (2022)

In Vitro Activity of Essential Oils Against Gram-Positive and Gram-Negative Clinical Isolates, Including Carbapenem-Resistant Enterobacteriaceae
por: Patterson, Jan E, et al.
Publicado: (2019)

Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance
por: Zhang, Fan, et al.
Publicado: (2018)

710. In Vitro Activity and Performance of Available Susceptibility Testing Methods for Eravacycline Against Carbapenem-Resistant Enterobacteriaceae (CRE)
por: Jones, Chelsea E, et al.
Publicado: (2019)

Synergistic antibacterial activity of silver nanoparticles biosynthesized by carbapenem-resistant Gram-negative bacilli
por: Haji, Sayran Hamad, et al.
Publicado: (2022)

Mechanism of Eravacycline Resistance in Clinical Enterococcus faecalis Isolates From China
por: Wen, Zewen, et al.
Publicado: (2020)

Emergence of Carbapenem-Resistant Gram-Negative Isolates in Hospital Settings in Djibouti
por: Ragueh, Ayan Ali, et al.
Publicado: (2023)

2132. Multicenter Evaluation of Eravacycline MIC Results for Enterobacteriaceae Using MicroScan Dried Gram-Negative MIC Panels
por: Traczewski, Maria M, et al.
Publicado: (2019)

In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China
por: Zhao, Chunjiang, et al.
Publicado: (2019)

In vitro Susceptibility Testing of Essential Oils against Gram-positive and Gram-negative Clinical Isolates, including Carbapenem-resistant Enterobacteriaceae (CRE)
por: Patterson, Jan E, et al.
Publicado: (2017)

2137. Real World Experience with Eravacycline for the Treatment of Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
por: Lim, Andy, et al.
Publicado: (2023)

Drug Resistance and Molecular Epidemiology of Carbapenem Resistant Gram-negative Bacilli Isolates
por: Naim, Huma, et al.
Publicado: (2018)

Molecular characterization of carbapenem-resistant Gram-negative bacilli clinical isolates in Algeria
por: Bourafa, Nadjette, et al.
Publicado: (2018)

Molecular characteristics of carbapenem-resistant gram-negative bacilli in pediatric patients in China
por: Yin, Lijun, et al.
Publicado: (2023)

Evaluating the Efficacies of Carbapenem/β-Lactamase Inhibitors Against Carbapenem-Resistant Gram-Negative Bacteria in vitro and in vivo
por: El Hafi, Bassam, et al.
Publicado: (2019)

Trends and correlation between antibacterial consumption and carbapenem resistance in gram-negative bacteria in a tertiary hospital in China from 2012 to 2019
por: Liang, Chunhong, et al.
Publicado: (2021)

Investigation and analysis of carbapenem-resistant gram-negative bacterial infection rates across hospitals in Shandong Province in China
por: Liu, Keke, et al.
Publicado: (2022)

Omadacycline, Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus Activity In Vitro
por: Li, Anqi, et al.
Publicado: (2023)

Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
por: Nordmann, Patrice, et al.
Publicado: (2019)

Global Threat of Carbapenem-Resistant Gram-Negative Bacteria
por: Jean, Shio-Shin, et al.
Publicado: (2022)

Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens
por: Cruz-López, Flora, et al.
Publicado: (2022)

Dissemination of carbapenem resistance and plasmids encoding carbapenemases in Gram-negative bacteria isolated in India
por: Manohar, Prasanth, et al.
Publicado: (2021)

616. Evaluation of In Vitro Susceptibility to Ceftazidime/Avibactam of Clinical Isolates of Carbapenem Nonsusceptible Gram-Negative Bacilli from Colombia
por: Appel, Tobias M, et al.
Publicado: (2019)

In Vitro Activities of Aztreonam-Avibactam, Eravacycline, Cefoselis, and Other Comparators against Clinical Enterobacterales Isolates: a Multicenter Study in China, 2019
por: Chen, Jiawei, et al.
Publicado: (2023)

In vitro activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancer
por: Rolston, Kenneth, et al.
Publicado: (2023)

In vitro activity of eravacycline against common ribotypes of Clostridioides difficile
por: Bassères, Eugénie, et al.
Publicado: (2020)

Comparison of Risk Factors and Outcomes in Carbapenem-Resistant and Carbapenem-Susceptible Gram-Negative Bacteremia
por: Cetin, Sinan, et al.
Publicado: (2021)

Effectiveness of a double-carbapenem combinations against carbapenem-resistant Gram-negative bacteria
por: Lu, Jiayue, et al.
Publicado: (2022)

Evaluation of different methods for in vitro susceptibility testing of colistin in carbapenem resistant Gram-negative bacilli
por: Rout, Bidyutprava, et al.
Publicado: (2023)

Phenotypic characterization of carbapenem non-susceptible gram-negative bacilli isolated from clinical specimens
por: Abdeta, Abera, et al.
Publicado: (2021)

Cerium Oxide Nanoparticles and Their Efficient Antibacterial Application In Vitro against Gram-Positive and Gram-Negative Pathogens
por: Pop, Oana L., et al.
Publicado: (2020)

The role of carbapenems in initial therapy for serious Gram-negative infections
por: Rahal, James J
Publicado: (2008)

Optimizing the use of carbapenems in the face of increasing Gram-negative resistance
por: Ramphal, Reuben
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_j0ccrceuj36oehf21a13m1vd31